SEPN SEPTERNA INC

Septerna to Present at Jefferies Global Healthcare Conference

Septerna to Present at Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 3:45 p.m. ET in New York.

A live webcast of the presentation will be available and in the investors section of the company’s website at . The webcast will be archived for at least 30 days following the presentation.

About Septerna

Septerna, Inc. is a biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Septerna was launched by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs. For more information, please visit .

Investor Contact:

Renee Leck

THRUST Strategic Communications



EN
29/05/2025

Underlying

SEPNSEPTERNA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SEPTERNA INC

 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna to Present at TD Cowen 46th Annual Health Care Conference

Septerna to Present at TD Cowen 46th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 p.m. ET in Boston. A live webcast of the presentation will be available in the investors section of the company’s website at ...

February 24, 2026 1 EN
 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced today that on February 6, 2026, the company’s Board of Directors granted an inducement award to Mark A. Wilson, Septerna’s Chief Legal Officer, consisting of a non-qualified stock option to purchase 165,000 shares of common stock under the Company’s 2026 Inducement Plan. The award was granted as an inducem...

February 10, 2026 1 EN
 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for th...

Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the company will present data from its Phase 1 clinical trial of SEP-631 at the 2026 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, taking place February 27-March 2, 2026, in Philadelphia. SEP-631 is a ...

February 10, 2026 1 EN
 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna Expands Leadership with Appointment of Industry Veteran Mark ...

Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Mark A. Wilson as Chief Legal Officer. Mr. Wilson is an accomplished pharmaceutical and biotech executive with more than 25 years of experience across intellectual property, corporate legal, strategic collaborations and corporate governance matters. ...

January 8, 2026 1 EN
 PRESS RELEASE
Free
SEPN SEPTERNA INC

Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference

Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:45 p.m. PT in San Francisco. A live webcast of the presentation will be available in the investors section of the co...

December 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch